A recent court decision in the United States raises questions about the Food and Drug Administration's (FDA) ability to advise the public about the safety and efficacy of medical products and to influence the off-label use of drugs.
The complete, unedited article Perspective, written by Tina Watson, B.A. and Christopher Robertson, J.D., Ph.D., was published by the New England Journal of Medicine on December 16, 2023.
Read More
